GeneDx Holdings Corp. is a genomics company that focuses on delivering exome and genome sequencing services for the diagnosis of genetic disorders. The firm combines clinical laboratory expertise with a proprietary dataset called GeneDx Infinity to power its ExomeDx and GenomeDx tests which have received FDA Breakthrough Device Designation. Founded in 2000 by scientists from the National Institutes of Health the company built one of the world’s largest rare disease repositories and continues to develop rapid ultra rapid genome sequencing protocols. GeneDx aims to shift genetic testing from reactive panel based approaches to comprehensive exome and genome analysis that can be used as a first tier test across pediatric outpatient neonatal intensive care and prenatal settings. The firm also seeks to expand its data and biopharma solutions business by leveraging its extensive genomic and phenotypic information to support drug discovery clinical trial recruitment and real world evidence generation. GeneDx Holdings Corp. operates CLIA certified high complexity laboratories in Gaithersburg Maryland and holds additional state licenses in New York California Pennsylvania and Rhode Island. The company’s mission emphasizes empowering patients to live their healthiest life through genomics while promoting equity simplicity and transparency in all its activities.

GeneDx Holdings Corp. generates revenue primarily from the sale of diagnostic test reports for exome and genome sequencing. The core offering includes ExomeDx GenomeDx and related rapid turnaround products that are billed to third party payors patients business to business clients and healthcare partners. In addition to test revenue the company earns income from data and information solutions that provide access to the GeneDx Infinity dataset variant interpretation pipelines and cloud based analysis services for biopharma and research organizations. Newborn screening products and associated information services represent an emerging revenue stream as the firm expands its genome based screening initiatives. The firm also receives modest revenue from international referral sources which currently account for about 1.5 percent of total sales. Revenue exhibits modest seasonal variation with higher volumes in the fourth quarter attributable to patients meeting annual insurance deductibles and lower volumes in the first quarter. Over time GeneDx expects to increase the proportion of revenue derived from data solutions newborn screening and information services while maintaining a strong foundation in diagnostic testing.

GeneDx Holdings Corp. holds a leading position in the genetic diagnostics industry due to the scale and diversity of its GeneDx Infinity dataset which contains over 2.5 million tests including more than one million exomes and genomes and a substantial proportion of non European ancestry samples. This extensive resource enables the firm to deliver high diagnostic yield and reduced uncertain results compared to competitors that rely on smaller or less diverse public databases. The company’s competitive advantages include a CLIA accredited high complexity laboratory a team of over one hundred medical doctors and PhDs and more than one hundred fifty genetic counselors who provide expert interpretation. GeneDx has integrated artificial intelligence tools such as the Multiscore gene ranker to accelerate variant analysis and improve turnaround time. The firm’s ExomeDx and GenomeDx assays have earned FDA Breakthrough Device Designation underscoring their clinical validity and potential for rapid regulatory pathways. Principal competitors in the market include Baylor Genetics Tempus through its Ambry Genetics subsidiary Variantyx Rady Children’s Hospital and various academic and commercial laboratories. While Illumina Inc. supplies sequencing equipment and reagents it also operates as a competitor in the broader genetic information space. GeneDx differentiates itself through its focus on rare disease depth its longitudinal patient data and its commitment to providing actionable reports that are accessible to non genetics clinicians.

GeneDx Holdings Corp. serves a varied customer base that includes hospitals academic medical centers specialty clinics and individual clinicians. Specific collaborators mentioned in the filing include Seattle Children’s Hospital and the University of Washington for the SeqFirst study and New York‑Presbyterian Columbia University New York State Department of Health and Illumina Inc. for the GUARDIAN study. The company’s primary payors are third party insurance companies managed care organizations and federal and state healthcare programs such as Medicare and Medicaid. Patients themselves also contribute revenue particularly for self pay or high deductible scenarios. Business to business clients consist of biopharma firms that utilize GeneDx’s data and information solutions for clinical trial recruitment target identification and real world evidence generation. Additionally the firm works with public health agencies and advocacy groups to advance newborn screening initiatives and to expand access to genomic testing in underserved populations. The customer base spans pediatric neurologists geneticists general pediatricians neonatologists and prenatal care providers reflecting the firm’s strategy to make exome and genome testing a frontline diagnostic tool across multiple care settings.